Scholar Rock Holding Corp

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Scholar Rock advances myostatin programs, eyes regulatory milestones in 2024

Scholar Rock's Q3 performance reflects progress in myostatin programs and expansion into cardiometabolic disorders, supported by strong financials and partnerships.
The company's focus on myostatin biology, promising results of apitegromab and SRK-439, and engagement with regulatory authorities position them for future success.
While facing challenges in statistical assumptions, patient variability, and therapy safety, Scholar Rock's deep understanding of myostatin presents opportunities for growth and innovation.

Scholar Rock excels in Q3 with SMA breakthrough and strong financial backing

Scholar Rock's Q3 performance showcases promising advancements in SMA treatment and strategic initiatives to drive future growth and commercial success.
The company's strong financial position, diverse pipeline, and focus on patient-centric care position them well for potential market leadership.
While facing challenges in regulatory approval and market competition, Scholar Rock's proactive approach and innovative drug candidates present significant opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET).

Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in November 2022. The award is subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Plan (the “Plan”) and form of stock option agreement thereunder.

Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2022.

Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz, M.D.

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Shares are down 70% thus far in 2022. TOPAZ data update for apitegromab in SMA was encouraging (as reflected in increases in HFMSE and RULM scores).

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present Data from DRAGON, a Phase 1 proof-of-concept study of SRK-181 in patients with advanced solid tumors, at SITC Annual Meeting.

Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at WMS Congress and International Scientific Congress on Spinal Muscular Atrophy.

Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2022. “We are pleased to have reported important progress with our two clinical programs during the second quarter. Enrollment continues to advance in our pivotal Phase 3 SAPPHIRE trial for

Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock's Board of Directors as an independent director.

Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the “Muscle Beach” panel for the 2022 Wedbush PacGrow Healthcare Conference, being held virtually on August 9, 2022, at 2:20 pm ET. A live webcast of the panel may be accessed by visiting the Investors & Media section of the

Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.

Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference

The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Scholar Rock Holding Corporation (SRRK) Have the Potential to Rally 246% as Wall Street Analysts Expect?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced an e-poster presentation on the ongoing SAPPHIRE Phase 3 clinical trial in spinal muscular atrophy (SMA) at ICNMD 2022.

Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

A venture capital group significantly increased its stake in the company.

Why Scholar Rock Stock Flew High Today

The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Scholar Rock Holding Corporation (SRRK)? Wall Street Analysts Think 394%

Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months.

Why Scholar Rock Shares Are Trading Higher Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has entered into a securities purchase agreement with certain institutional investors to sell, in a registered direct offering, 16,326,530 shares of common stock and, in lieu of common stock, pre-funded warrants to purchase 25,510,205 shares of common stock

Scholar Rock Announces $205 Million Registered Direct Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24-months of treatment, which support sustained and continued improvement with apitegromab for non-ambulatory patients with Types 2 and 3 SMA receiving an SMN therapy. Detailed

Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA Research and Clinical Care meeting, which is being held in conjunction with Cure SMA's Annual SMA Conference (June 15-19, 2022). “We are eager to pr

Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

The mean of analysts' price targets for Scholar Rock Holding Corporation (SRRK) points to a 412.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 413%: Read This Before Placing a Bet

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 8:00 a.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com.

News for Scholar Rock Holding Corp Stock (SRRK)